Last reviewed · How we verify

Coreg (CARVEDILOL)

Waylis · FDA-approved approved Small molecule Verified Quality 70/100

Coreg works by blocking the effects of the hormone epinephrine on the heart, reducing its workload and improving its function.

Coreg (Carvedilol) is a small molecule alpha-adrenergic blocker developed by SmithKline Beecham and currently owned by Wyeth (now part of Pfizer). It targets the beta-2 adrenergic receptor and is used to treat chronic heart failure, hypertensive disorder, and left ventricular cardiac dysfunction. Coreg is off-patent and has multiple generic manufacturers. The drug has a half-life of 2.4 hours and bioavailability of 25%. Key safety considerations include its potential to cause bradycardia and hypotension.

At a glance

Generic nameCARVEDILOL
SponsorWaylis
Drug classalpha-Adrenergic Blocker [EPC]
TargetBeta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved
First approval1995

Mechanism of action

Carvedilol is racemic mixture in which nonselective -adrenoreceptor blocking activity is present in the S(-) enantiomer and 1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol has no intrinsic sympathomimetic activity.

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: